Sarepta pops amid Duchenne policy forum

Sarepta Therapeutics (SRPT +14.4%) is sharply higher amid today's Duchenne Policy Forum from Parent Project Muscular Dystrophy (live stream here) where the FDA's Janet Woodcock may have made some comments supportive of eteplirsen's regulatory timelines.

From other sites
Comments (1)
  • jimgutner
    , contributor
    Comments (72) | Send Message
    I find this tweet and move in the stock quite interesting when the CEO of Sarepta communicated that the FDA had reservations about the technology and the use of the markers they are using.
    12 Dec 2013, 01:50 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs